MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

Search

Recursion Pharmaceuticals Inc

Fechado

SetorSaúde

6.78 15.5

Visão Geral

Variação de preço das ações

24h

Atual

Mín

5.87

Máximo

6.81

Indicadores-chave

By Trading Economics

Rendimento

31M

-172M

Vendas

4.4M

19M

Margem de lucro

-899.843

Funcionários

800

EBITDA

44M

-148M

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+1.02% upside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-138M

2.4B

Abertura anterior

-8.72

Fecho anterior

6.78

Sentimento de Notícias

By Acuity

50%

50%

166 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Recursion Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

15 de out. de 2025, 23:25 UTC

Grandes Movimentos do Mercado

Salesforce Rises on New FY30 Financial Targets

15 de out. de 2025, 18:52 UTC

Ganhos
Grandes Movimentos do Mercado

Prologis Shares Gain on Raised Outlook, Data Center Growth

15 de out. de 2025, 18:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Constellation Software to Buy U.K.'s Tecvia Holding

15 de out. de 2025, 17:19 UTC

Aquisições, Fusões, Aquisições de Empresas

Drahi's Altice Rejects $20 Billion Joint Offer From Peers -- 2nd Update

15 de out. de 2025, 17:11 UTC

Aquisições, Fusões, Aquisições de Empresas

Anglo American, MMG Offer Concessions to EU Merger Watchdog in Nickel Deal Probe

15 de out. de 2025, 23:48 UTC

Conversa de Mercado

Gold Steady, Supported by Expectations of Ongoing Central Bank Purchases -- Market Talk

15 de out. de 2025, 23:38 UTC

Conversa de Mercado

Nikkei May Rise, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15 de out. de 2025, 22:37 UTC

Conversa de Mercado

Economic Stars Are Aligning for RBA -- Market Talk

15 de out. de 2025, 21:44 UTC

Ganhos

Stock Rally Is Lifting Wealth Managers. How Much Is Charles Schwab Benefiting? -- Barrons.com

15 de out. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Financial Services Roundup: Market Talk

15 de out. de 2025, 20:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Restaurant Brands Recommends Hldrs Do Not Tender Their Shrs to the Offer >QSR.T

15 de out. de 2025, 20:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Restaurant Brands Notified of Unsolicited Mini-Tender Offer to Buy Shrs at $28.80/Shr

15 de out. de 2025, 20:43 UTC

Aquisições, Fusões, Aquisições de Empresas

Restaurant Brands Notified of Unsolicited Mini-Tender Offer by NY Stk and Bond LLC to Purchase Up to 10,000 Common Shrs >QSR.T

15 de out. de 2025, 20:34 UTC

Ganhos

Prologis Raises Outlook as Warehouse Leasing Picks Up -- WSJ

15 de out. de 2025, 20:31 UTC

Aquisições, Fusões, Aquisições de Empresas

RBI Recommends Hldrs Reject NYSB's "Mini-Tender Offer"

15 de out. de 2025, 20:17 UTC

Aquisições, Fusões, Aquisições de Empresas

GE Vernova Stock Feill With Latest Call to Sell -- Barrons.com

15 de out. de 2025, 19:06 UTC

Ganhos

These Stocks Are Moving the Most Today: Bank of America, Morgan Stanley, ASML, AMD, Nvidia, Bunge, Progressive, Abbott, and More -- Barrons.com

15 de out. de 2025, 19:04 UTC

Conversa de Mercado

Oil Futures Post Back-to-Back Losses -- Market Talk

15 de out. de 2025, 18:46 UTC

Conversa de Mercado

U.S. Natural Gas Futures Slip Ahead of Storage Data -- Market Talk

15 de out. de 2025, 18:23 UTC

Ganhos

This Insurer Is the One of the Worst Stocks in the S&P 500 Today. Here's Why. -- Barrons.com

15 de out. de 2025, 17:37 UTC

Aquisições, Fusões, Aquisições de Empresas

Constellation Software's Harris Operating Group Enters Into Agreement To Acquire TECVIA Holding GmbH >CSU.T

15 de out. de 2025, 17:34 UTC

Conversa de Mercado

Oil Futures Lose Ground on Trade, Oversupply Concerns -- Market Talk

15 de out. de 2025, 16:57 UTC

Ganhos

The Nation's Biggest Banks Are Saying the Economy Is Still Strong -- WSJ

15 de out. de 2025, 16:51 UTC

Aquisições, Fusões, Aquisições de Empresas

EssilorLuxottica Doesn't Disclose Financial Details

15 de out. de 2025, 16:50 UTC

Aquisições, Fusões, Aquisições de Empresas

EssilorLuxottica: RetinAI Partners With Pharmaceutical Companies, Research Organizations

15 de out. de 2025, 16:49 UTC

Aquisições, Fusões, Aquisições de Empresas

EssilorLuxottica: Deal Reinforces the Group's Med-Tech Journey

15 de out. de 2025, 16:48 UTC

Aquisições, Fusões, Aquisições de Empresas

EssilorLuxottica: Ikerian Specializes in Artificial Intelligence, Data Management in Eyecare

15 de out. de 2025, 16:48 UTC

Aquisições, Fusões, Aquisições de Empresas

EssilorLuxottica: Ikerian Is a Health Technology Company, Operating Under the RetinAI Brand

15 de out. de 2025, 16:47 UTC

Aquisições, Fusões, Aquisições de Empresas

EssilorLuxottica Buys Ikerian

15 de out. de 2025, 16:34 UTC

Conversa de Mercado

AMD Data Center Agreements Will Provide Big Revenue Growth -- Market Talk

Comparação entre Pares

Variação de preço

Recursion Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

1.02% parte superior

Previsão para 12 meses

Média 5.95 USD  1.02%

Máximo 8 USD

Mínimo 3 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Recursion Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

5 ratings

1

Comprar

4

Manter

0

Vender

Pontuação Técnica

By Trading Central

4.15 / 4.75Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

166 / 371 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
help-icon Live chat